Compare HUBS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBS | CORT |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | 730 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.7B |
| IPO Year | 2014 | 2001 |
| Metric | HUBS | CORT |
|---|---|---|
| Price | $191.71 | $89.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 32 | 5 |
| Target Price | ★ $435.19 | $96.50 |
| AVG Volume (30 Days) | ★ 1.5M | 957.9K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 855.56 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $375,612,000.00 | ★ $761,407,000.00 |
| Revenue This Year | $20.46 | $26.08 |
| Revenue Next Year | $16.01 | $26.98 |
| P/E Ratio | $309.82 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $169.63 | $28.66 |
| 52 Week High | $568.16 | $91.00 |
| Indicator | HUBS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 80.68 |
| Support Level | $187.45 | $76.41 |
| Resistance Level | $258.01 | N/A |
| Average True Range (ATR) | 9.57 | 3.76 |
| MACD | 1.82 | -0.09 |
| Stochastic Oscillator | 88.34 | 94.20 |
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.